Jahanzeb Khan
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Brigham Young University (2000); Georgia Institute of Technology (2020); University of Kansas (2000); University of Azad Jammu and Kashmir (2023); Gomal University (2014–2017); Florida International University (2000); Rega Institute for Medical Research (2000); Dow University of Health Sciences (2021–2022); Baptist Health Foundation (2021–2022); Mirpur University of Science and Technology (2023); Manipal University Jaipur (2021–2023)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Jahanzeb Khan's research focuses on health disparities and outcomes, particularly within the context of type 2 diabetes and its associated complications among Pakistani Muslim populations. He has investigated asymptomatic urinary tract infections and their risk factors in this demographic, as well as the safety and efficacy of specific diabetes medications like Empagliflozin and Semaglutide. Khan's work also extends to exploring potential adverse events related to medical interventions, including a case study on a membranous nephropathy linked to a COVID-19 vaccine and a case report on Semaglutide potentially causing focal segmental glomerulosclerosis.
His research interests are further indicated by publications on environmental concerns, including heavy metal contamination in groundwater and the efficacy of adsorbents for metal removal. Khan's academic contributions are reflected in his h-index of 7, with 25 publications and 189 citations. He collaborates with colleagues at the University of Arkansas for Medical Sciences, including Luis A. Juncos, Umair Ali, Gerry Ezell, and Wahida Rashid.
Metrics
- h-index: 7
- Publications: 25
- Citations: 191
Selected Publications
-
Semaglutide (Ozempic), a Possible Cause of Focal Segmental Glomerulosclerosis (FSGS) (2023)
-
A Case of Membranous Nephropathy Hypothesized to be Associated With COVID-19 Vaccine (2022)
Collaboration Network
Top Collaborators
- A Case of Membranous Nephropathy Hypothesized to be Associated With COVID-19 Vaccine
- A Case of Membranous Nephropathy Hypothesized to be Associated With COVID-19 Vaccine
- A Case of Membranous Nephropathy Hypothesized to be Associated With COVID-19 Vaccine
- A Case of Membranous Nephropathy Hypothesized to be Associated With COVID-19 Vaccine
- Semaglutide (Ozempic), a Possible Cause of Focal Segmental Glomerulosclerosis (FSGS)
- Semaglutide (Ozempic), a Possible Cause of Focal Segmental Glomerulosclerosis (FSGS)
- Semaglutide (Ozempic), a Possible Cause of Focal Segmental Glomerulosclerosis (FSGS)
- Semaglutide (Ozempic), a Possible Cause of Focal Segmental Glomerulosclerosis (FSGS)
- Semaglutide (Ozempic), a Possible Cause of Focal Segmental Glomerulosclerosis (FSGS)
Similar Researchers
Based on overlapping research topics